Abstract:Small molecules that can restore biological function to the p53 mutants found in human cancers have been highly sought to increase the anticancer efficacy. In efforts to generate hybrid anticancer drugs that can impact two or more targets simultaneously, we designed and developed piperlongumine (PL) derivatives with an aryl group inserted at the C-7 position. This insertion bestowed a combretastatin A4 (CA4, an established microtubule disruptor) like structure while retaining the piperlongumine configuration. The new compounds exhibited potent antiproliferative activities against eight cancer cell lines, in particular, were more cytotoxic against the SKBR-3 breast cancer cells which harbor a R175H mutation in p53 suppressor. KSS-9, a representative aryl PL chosen for further studies induced abundant ROS generation and protein glutathionylation. KSS-9 strongly disrupted the tubulin polymerization in vitro, destabilized the microtubules in cells and induced a potent G2/M cell cycle block. More interestingly, KSS-9 showed the ability to reactivate the p53 mutation and restore biological activity to the R175H mutant protein present in SKBR3 cells. Several procedures, including immunocytochemistry using conformation-specific antibodies for p53, immunoprecipitation combined with western blotting, electrophoretic shift mobility shift assays showed a reciprocal loss of mutant protein and generation of wild-type like protein. p53 reactivation was accompanied by the induction of the target genes, MDM2, p21cip1 and PUMA. Mechanistically, the redox-perturbation in cancer cells by the hybrid drug appears to underlie the p53 reactivation process. This anticancer drug approach merits further development.

Unified Flexible Total Synthesis of Chlorofusin and Artificial Click Mimics As Antagonists Against P53–hdm2 Interactions

Stereodivergent total synthesis of chlorofusin and its all seven chromophore diastereomers

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Total Synthesis, Assignment of Absolute Stereochemistry, and Structural Revision of Chlorofusin.

Synthesis of the Cyclic Nonapeptide of Chlorofusin Using a Convergent [3+3+3]-Fragment Coupling Strategy

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Bromoetherification-Based Strategy Towards the Spirocyclic Chromophore of Chlorofusin

Click Chemistry in Natural Product Modification

Total Synthesis Of (+)-Alsmaphorazine C And Formal Synthesis Of (+)-Strictamine: A Photo-Fries Approach

Total synthesis, structure revision and cytotoxic activity of Sch 53825 and its derivatives

Discovery of spirooxindole–ferrocene hybrids as novel MDM2 inhibitors

Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3′-Spirooxindoles Fused with Tetrahydrothiopyrans As Novel P53-Mdm2 Inhibitors

Facile Entry to Pharmaceutically Important 3-Difluoromethyl-Quinoxalin-2-Ones Enabled by Visible-Light-Driven Difluoromethylation of Quinoxalin-2-Ones

Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists.

Total Synthesis of Anti-Hiv Agent Chloropeptin I.

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

1,4‐Thienodiazepine‐2,5‐diones Via MCR (I): Synthesis, Virtual Space and P53‐mdm2 Activity

Diversity-oriented synthesis and antifungal activities of novel pimprinine derivative bearing a 1,3,4-oxadiazole-5-thioether moiety

Total Synthesis of the G2/M DNA Damage Checkpoint Inhibitor Psilostachyin C.

Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties